Philips Evolves its Ultrasound Line with New Radiology Imaging Tools and Features to Increase Diagnostic Confidence and Workflow Efficiency
November 18, 2021 – Philips Royal, a healthcare technology leader, announced that it has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for its new liver fat quantification tools as part of the latest release of its EPIQ Elite and Affiniti ultrasound systems, bringing the cost and affordability advantages of ultrasound for the diagnosis of early stage liver disease. Presented to this year Radiological Society of North America (RSNA), the new tools will allow clinicians to monitor liver health.
Fatty liver disease is the most common and earliest stage of chronic liver disease. The incidence of non-alcoholic fatty liver disease (NAFLD) is increased by various risk factors, including type 2 diabetes and obesity. It is estimated that NAFLD may be present in approximately 25% of the world’s population.1 NAFLD includes milder fatty liver disease, as well as more severe forms that include inflammation, a condition called non-alcoholic steatohepatitis (NASH), and fibrosis. Research suggests that early intervention empowers patients to make lifestyle changes that can help prevent liver disease,1 while early assessment of fatty liver disease is essential to potentially reverse this progression of liver disease.2
“With a quantitative way of measuring liver fat, it’s much easier for us to let the attending physician know where the patient is quantitatively on the NAFLD spectrum,” said Richard G. Barr, MD, Ph.D. , President, Radiology Consultant Inc. and Medical Director of Southwoods Imaging. “With traditional grayscale imaging, we could only tell whether the liver had a high degree of fatty infiltration or whether it was normal, but it was very difficult to assess whether the fatty liver was benign. , moderate or severe. The attenuation imagery now gives us a numerical value that will allow us to follow the patient over time. With the combination of a quantitative assessment of liver fat and stiffness, the likelihood of NASH can be assessed. “
With the extended remote functionality of Live collaboration On the EPIQ and Affiniti platforms, technicians can also securely access on-demand, real-time advice and decision support to improve diagnostic reliability and workflow efficiency during exams.
“[The] This announcement demonstrates the continued advancement of our ultrasound portfolio to increase diagnostic confidence and workflow efficiency, ”said Jeff Cohen, general manager of ultrasound at Philips. “The quantification of hepatic fat accessible by ultrasound is a screening and early diagnosis tool that will allow many more patients to take charge of their health by making simple changes to their lifestyle. “
Improve the diagnosis and treatment of early and late stage liver disease
Philips Ultrasound Systems EPIQ and Affiniti on version 9.0 now support radiologists and hepatologists in the diagnosis and treatment of early to advanced liver disease, making it easier to conduct longitudinal studies to assess disease progression hepatic. With this latest release, the company further strengthens its liver solution and extends its full availability to Affiniti 70 and Affiniti 50, supported by the innovative PureWave C5-1 Curved transducer, now also available on Affiniti 50, to improve confidence abdominal diagnosis, hepatology, as well as vascular and gynecological ultrasound examinations. The new liver fat quantification tools complement the company’s existing ultimate solution for liver assessment with real-time shear wave imaging, contrast enhanced ultrasound (CEUS), and fusion and navigation. Liver fat quantification tools, which provide ease of use as well as intuitive workflow and reporting, are available on the C5-1 transducer and the mC7-2 small footprint MicroConvex transducer, to accommodate to different body types, from smaller patients to high BMI patients.3
Philips liver fat quantification solution launched at RSNA 2021
Philips will launch its liver fat quantification solution at the Radiological Society of North America (RSNA) annual meeting later this month. For more information on Philips Liver Fat Quantification, including live demonstrations, follow @PhilipsLiveFrom for updates throughout the RSNA event. For more information on Philips’ liver ultrasound solutions portfolio, visit Philips Liver Assessment Webpage, and join Philips at RSNA 2021 where the company will highlight its latest portfolio of radiology workflow solutions and smart imaging systems connected to increase efficiency and diagnostic confidence in precision care and treatment.
1 Asrani et al. Burden of liver disease around the world. J Hepatology. 2019; 1.
2 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019; 70 (3): 531-544.
3 Chen J. Achieve dramatic improvements in the efficiency, sensitivity and bandwidth of ultrasonic transducers. Koninklijke Philips Electronics NV 2006.